Five Prime Therapeutics Inc (FPRX.OQ)
FPRX.OQ on NASDAQ Stock Exchange Global Select Market
16.99USD
26 Apr 2018
16.99USD
26 Apr 2018
Change (% chg)
$0.15 (+0.89%)
$0.15 (+0.89%)
Prev Close
$16.84
$16.84
Open
$16.84
$16.84
Day's High
$17.05
$17.05
Day's Low
$16.78
$16.78
Volume
7,258
7,258
Avg. Vol
221,414
221,414
52-wk High
$48.74
$48.74
52-wk Low
$15.74
$15.74
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Buy | -1.44 | December | 26 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 4 | 4 | 5 | 5 |
| (2) OUTPERFORM | 3 | 4 | 4 | 4 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.43 | 1.50 | 1.44 | 1.44 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 4 | 7.67 | 8.40 | 6.80 | 6.70 |
| Quarter Ending Sep-18 | 4 | 16.47 | 33.57 | 6.80 | 6.70 |
| Year Ending Dec-18 | 4 | 78.21 | 133.86 | 52.00 | 70.74 |
| Year Ending Dec-19 | 6 | 112.14 | 178.20 | 27.00 | 145.47 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 5 | -1.44 | -1.27 | -1.67 | -0.90 |
| Quarter Ending Sep-18 | 5 | -1.29 | -0.82 | -1.74 | -0.90 |
| Year Ending Dec-18 | 5 | -4.15 | -3.20 | -5.92 | -3.37 |
| Year Ending Dec-19 | 7 | -3.58 | -1.11 | -7.27 | -1.97 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 15.50 | 13.22 | 2.28 | 14.72 |
| Quarter Ending Sep-17 | 16.16 | 8.33 | 7.83 | 48.44 |
| Quarter Ending Jun-17 | 9.26 | 7.82 | 1.44 | 15.54 |
| Quarter Ending Mar-17 | 7.07 | 10.14 | 3.07 | 43.41 |
| Quarter Ending Dec-16 | 7.09 | 8.26 | 1.18 | 16.60 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | -1.31 | -1.04 | 0.27 | -20.44 |
| Quarter Ending Sep-17 | -1.24 | -1.54 | 0.30 | -24.27 |
| Quarter Ending Jun-17 | -1.21 | -1.58 | 0.37 | -30.85 |
| Quarter Ending Mar-17 | -1.02 | -1.21 | 0.19 | -18.05 |
| Quarter Ending Dec-16 | -0.57 | -0.73 | 0.16 | -27.33 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 7.67 | 7.67 | 7.67 | 9.23 | 6.70 |
| Quarter Ending Sep-18 | 16.47 | 16.47 | 16.47 | 17.62 | 6.70 |
| Year Ending Dec-18 | 78.21 | 78.21 | 74.33 | 77.55 | 70.74 |
| Year Ending Dec-19 | 112.14 | 112.14 | 130.67 | 132.53 | 145.47 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -1.44 | -1.44 | -1.44 | -1.30 | -0.90 |
| Quarter Ending Sep-18 | -1.29 | -1.29 | -1.29 | -1.08 | -0.90 |
| Year Ending Dec-18 | -4.15 | -4.15 | -4.15 | -4.30 | -3.37 |
| Year Ending Dec-19 | -3.58 | -3.58 | -3.58 | -3.31 | -1.97 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
Earnings vs. 
Estimates- BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO
- BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial
- BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics
- BRIEF-Five Prime Therapeutics Starts Patient Dosing In Phase 1 Trial In Antibody Study
- BRIEF-Five Prime Therapeutics Announces Executive Change